[go: up one dir, main page]

DOP2016000132A - Sistema de administración farmacologico - Google Patents

Sistema de administración farmacologico

Info

Publication number
DOP2016000132A
DOP2016000132A DO2016000132A DO2016000132A DOP2016000132A DO P2016000132 A DOP2016000132 A DO P2016000132A DO 2016000132 A DO2016000132 A DO 2016000132A DO 2016000132 A DO2016000132 A DO 2016000132A DO P2016000132 A DOP2016000132 A DO P2016000132A
Authority
DO
Dominican Republic
Prior art keywords
thermoplastic polymer
therapeutic agent
administration system
pharmacological administration
core
Prior art date
Application number
DO2016000132A
Other languages
English (en)
Inventor
Willy J H Verhoeven
Wouter De Graaff
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of DOP2016000132A publication Critical patent/DOP2016000132A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describe un sistema de administración farmacológico intravaginal que comprende (i) un núcleo que comprende un primer polímero termoplástico y un primer agente terapéutico, en el que el primer agente terapéutico se disuelve en el primer polímero termoplástico, y (ii) una capa externa que rodea el núcleo que comprende un segundo polímero termoplástico, en el que el primer agente terapéutico es menos permeable en el segundo polímero termoplástico que el primer polímero termoplástico, y un segundo agente terapéutico en forma sólida, en el que el segundo agente terapéutico está cargado en una porción de la capa externa.
DO2016000132A 2013-12-11 2016-06-10 Sistema de administración farmacologico DOP2016000132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361914500P 2013-12-11 2013-12-11
EP13196737 2013-12-11

Publications (1)

Publication Number Publication Date
DOP2016000132A true DOP2016000132A (es) 2016-07-31

Family

ID=49759119

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000132A DOP2016000132A (es) 2013-12-11 2016-06-10 Sistema de administración farmacologico

Country Status (23)

Country Link
US (1) US10413504B2 (es)
EP (1) EP3079660B1 (es)
JP (1) JP6251396B2 (es)
KR (1) KR101808977B1 (es)
CN (1) CN105979930B (es)
AP (1) AP2016009223A0 (es)
AU (1) AU2014363724B2 (es)
BR (1) BR112016013325B1 (es)
CA (1) CA2931559C (es)
CR (1) CR20160261A (es)
DO (1) DOP2016000132A (es)
EA (1) EA031802B1 (es)
HK (1) HK1224208A1 (es)
IL (1) IL245544A0 (es)
MA (1) MA39059A1 (es)
MD (1) MD20160079A2 (es)
MX (1) MX2016007681A (es)
PE (1) PE20160680A1 (es)
PH (1) PH12016501083A1 (es)
SG (1) SG11201604660VA (es)
SV (1) SV2016005214A (es)
TW (1) TW201607563A (es)
WO (1) WO2015086491A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3079659B1 (en) 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
MX2016008163A (es) 2013-12-19 2016-09-16 Procter & Gamble Formacion de fibras de queratina mediante el uso de una composicion reductora y una composicion fijadora.
CN105828786B (zh) 2013-12-19 2020-07-07 宝洁公司 使用包含选自-c(＝o)-、-c(＝o)-h和-c(＝o)-o-的官能团的an活性剂使角蛋白纤维成形
WO2015095685A1 (en) 2013-12-19 2015-06-25 The Procter & Gamble Company Shaping keratin fibres using 2-hydroxypropane-1,2,3-tricarboxylic acid and/or 1,2,3,4-butanetetracarboxylic acid
WO2015094837A1 (en) 2013-12-19 2015-06-25 The Procter & Gamble Company Shaping keratin fibres using carbonate ester
JP6396473B2 (ja) 2013-12-19 2018-09-26 ザ プロクター アンド ギャンブル カンパニー −ｃ（ｏｈ）−及び−ｃ（＝ｏ）ｏｈから選択される少なくとも２個の官能基を含む活性剤を使用した、ケラチン繊維の成形
JP6314235B2 (ja) 2013-12-19 2018-04-18 ザ プロクター アンド ギャンブル カンパニー オキソエタン酸及び／又はその誘導体を使用したヒトの毛髪をまっすぐにする方法
EP3082747B1 (en) 2013-12-19 2018-07-04 The Procter and Gamble Company Shaping keratin fibres using a sugar
EP3017809A1 (en) * 2014-11-07 2016-05-11 Ferring B.V. Drug-device unit containing quinagolide
MX2017008203A (es) 2014-12-19 2017-10-06 Procter & Gamble Metodo para dar forma a fibras de queratina.
MX2017008204A (es) 2014-12-19 2017-10-06 Procter & Gamble Conformacion de las fibras de queratina mediante el uso de arabinosa y carbonato de etileno.
US10945931B2 (en) 2015-06-18 2021-03-16 The Procter And Gamble Company Shaping keratin fibres using dialdehyde compounds
US20180228942A1 (en) * 2015-08-11 2018-08-16 Ptt Holding Aps A delivery device
EP3395335A1 (en) * 2017-04-24 2018-10-31 Kern Pharma, S.L. Vaginal ring for the simultaneous release of two active ingredients
DE102017113166A1 (de) * 2017-06-14 2018-12-20 Amw Gmbh Depotform zur Abgabe eines Östrogen-Wirkstoffs
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
BR112020023983A2 (pt) 2018-05-24 2021-02-23 Celanese Eva Performance Polymers Llc dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
WO2023141198A1 (en) * 2022-01-21 2023-07-27 The Population Council, Inc. Combination therapy intravaginal rings
WO2024115763A1 (en) 2022-12-02 2024-06-06 Vari Bioscience Gmbh Estriol vaginal ring

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US4237885A (en) 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4629449A (en) 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
EP0162492B1 (en) 1984-04-11 1989-08-02 Thiemann Arzneimittel GmbH Dosage units for controlled release of active material
US4596576A (en) 1984-10-12 1986-06-24 Akzo N.V. Release system for two or more active substances
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
WO1989009066A1 (en) 1988-03-24 1989-10-05 Bukh Meditec A/S Controlled release composition
US5766632A (en) 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception
JP3720386B2 (ja) 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
ES2166894T3 (es) 1995-07-04 2002-05-01 Akzo Nobel Nv Dispositivos anulares.
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
IL123813A0 (en) * 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
EP1037812B1 (en) 1997-12-12 2003-08-06 Akzo Nobel N.V. A package for a vaginal ring
CA2315103A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Crystalline teriparatide
US6579533B1 (en) 1999-11-30 2003-06-17 Bioasborbable Concepts, Ltd. Bioabsorbable drug delivery system for local treatment and prevention of infections
EP1372605A2 (en) 2001-03-27 2004-01-02 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
EP1427390A1 (en) 2001-08-31 2004-06-16 Schering Oy Drug delivery system
JP2005511515A (ja) 2001-09-28 2005-04-28 マクニール−ピーピーシー・インコーポレイテッド 互いに異なる形状の内側コア及び外側シェルを有する投薬形態
CN1242819C (zh) 2002-06-07 2006-02-22 上海市计划生育科学研究所 一种新型阴道环及制备方法
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
ES2442675T3 (es) 2003-07-10 2014-02-12 Warner Chilcott (Ireland) Limited Dispositivos intravaginales de suministro de fármacos
EP2295041A3 (en) * 2003-09-29 2012-01-04 Novo Nordisk Femcare AG HRT formulations
CN100531800C (zh) * 2004-03-24 2009-08-26 奥尔加侬股份有限公司 基于聚乙烯乙酸乙烯酯共聚物的药物递送系统
KR20060046263A (ko) * 2004-08-04 2006-05-17 도쿄파츠고교 가부시키가이샤 편평형 진동모터를 내장시킨 전자음향변환기
TW200727920A (en) 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
US20100136090A1 (en) * 2006-11-20 2010-06-03 N.V. Organon; Intervet International B.V. Helically-Shaped Drug Delivery System
WO2008100876A1 (en) 2007-02-12 2008-08-21 Particle Sciences, Inc. Delivery devices containing encapsulated and/or particle-bound active pharmaceutical ingredients
AR065816A1 (es) 2007-03-26 2009-07-01 Theramex Regimen anticonceptivo oral
JP5555162B2 (ja) 2007-09-07 2014-07-23 キュー エル ティー インク． 治療薬剤の持続放出のための薬物コア
TW200930343A (en) 2007-09-21 2009-07-16 Organon Nv Drug delivery system
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
MX2012000948A (es) 2009-07-21 2012-02-28 Population Council Inc Anillo vaginal gradiente multicapas.
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
TW201332585A (zh) 2012-02-14 2013-08-16 Chemo Res S L 核鞘藥物遞送裝置
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system

Also Published As

Publication number Publication date
MD20160079A2 (ro) 2016-10-31
HK1224208A1 (zh) 2017-08-18
EP3079660B1 (en) 2021-03-03
BR112016013325A2 (es) 2017-08-08
SV2016005214A (es) 2016-11-21
CA2931559A1 (en) 2015-06-18
SG11201604660VA (en) 2016-07-28
KR20160095110A (ko) 2016-08-10
US20150157561A1 (en) 2015-06-11
MA39059A1 (fr) 2018-08-31
US10413504B2 (en) 2019-09-17
WO2015086491A1 (en) 2015-06-18
JP6251396B2 (ja) 2017-12-20
AP2016009223A0 (en) 2016-05-31
MX2016007681A (es) 2016-10-14
AU2014363724B2 (en) 2017-02-23
EA201691193A1 (ru) 2016-09-30
PE20160680A1 (es) 2016-07-31
TW201607563A (zh) 2016-03-01
PH12016501083A1 (en) 2016-07-25
CA2931559C (en) 2018-03-13
JP2016539991A (ja) 2016-12-22
AU2014363724A1 (en) 2016-05-26
IL245544A0 (en) 2016-06-30
KR101808977B1 (ko) 2017-12-13
BR112016013325B1 (pt) 2022-11-29
CN105979930B (zh) 2019-11-19
EA031802B1 (ru) 2019-02-28
EP3079660A1 (en) 2016-10-19
CR20160261A (es) 2016-08-16
CN105979930A (zh) 2016-09-28

Similar Documents

Publication Publication Date Title
DOP2016000132A (es) Sistema de administración farmacologico
DOP2010000253A (es) Sistema de administracion de drogas con efecto estabilizante
CR20140487A (es) Peliculas de capas multiples capaces de liberar ingredientes activos por un periodo limitado de tiempo
PE20150129A1 (es) Formulacion de farmaco de liberacion retardada
AR081113A1 (es) Liberacion pulsatil de medicamentos desde un tapon de punctum
ECSP10010079A (es) Sistema para el suministro de una droga
IL299897B1 (en) Multi-unit drug delivery devices and methods
MX2018014906A (es) Composiciones farmaceuticas nasales con un excipiente poroso.
AR062321A1 (es) Sistema de liberacion controlada y metodo para fabricarlo
BR112016012615A8 (pt) sistemas, e kit
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
CL2015001882A1 (es) Sistema de entrega de fragancias
AR061860A1 (es) Prepracion farmaceutica para la administracion oral con liberacion controlada de ingrediente activo en el intestino delgado y metodo para su fabricacion
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
MX2020003667A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.
MX2015008525A (es) Material polimerico celular.
AR089765A1 (es) Un sistema para el suministro de un farmaco
CL2016000944A1 (es) Nueva formulación de ganadotropinas
CO2018002590A2 (es) Sistemas y métodos para utilizar estructuras biomiméticas que proporcionan comunicación en tejidos vivientes
AR099135A1 (es) Administración retardada de sustancias químicas en un pozo
CL2015002560A1 (es) Un método para tratar infecciones, enfermedades o desordenes de la unidad ungueal, con un dispositivo para implantar una composición en una ubicación determinada y un régimen de dosificación para tratar una enfermedad o trastorno de la unidad ungueal.
MX2019004938A (es) Cápsula compleja que contiene esomeprazol y método de preparación de esta.
NI201600077A (es) Sistema de administración farmacológico
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
CU20160026A7 (es) Formulación de fármaco de liberación retardada